Citi raised the firm’s price target on Argenx to $512 from $463 and keeps a Buy rating on the shares following the approval of Vyvgart Hytrulo in CIDP with a broad label that covers both treatment-experienced and treatment-naive CIDP patients. Following the approval, the firm is raising its view of the odds of success in CIDP to 100% from 90% and adjusting its expectations around the revenue ramp, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Unveils Innovative CIDP Treatment VYVGART Hytrulo
- argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
- Argenx announces FDA approval of VYVGART Hytrulo
- Argenx Unveils ‘Vision 2030’ for Transforming Autoimmunity
- argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024